Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combining MEK inhibitors with BH3 mimetics, which competitively bind to BCL-XL or MCL-1 and liberate BIM, can induce apoptosis and lead to regression of KRAS-mutant tumors12,16,17.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [17]
In the citing paper
“Our finding that LKB1 regulates the apoptotic dependency of KRAS-mutant lung cancers is unexpected, as genomic features associated with sensitivity to BH3 mimetics in oncogene-addicted solid tumors have been elusive12,16,17.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [17]
In the citing paper
“Inhibition of MEK/ERK signaling leads to BIM accumulation and increases apoptotic priming in oncogene-driven cancers treated with various targeted therapies, driving cells into an MCL-1 and/or BCL-XL dependent state15,17.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [17]
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“In addition, it is possible that certain tumour types that do not harbour mutations in genes encoding oncogenic kinases may still benefit from a combination therapy of targeted OKI plus a BH3 mimetic, similar to the benefit seen for erlotinib when used as a single agent across all subgroups of NSCL”
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679 · cited 1×
“BIM and PUMA can bind and sequester all anti-apoptotic Bcl-2 family members with high affinity and are thus potent killers, whereas other BH3-only proteins, such as Bcl-2 antagonist of cell death ( BAD ) and NOXA (also known as PMAIP1), bind only certain anti-apoptotic members (BAD binds BCL-2, BCL-X L (also known as…”
BackgroundSelf-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“, such as the T790M mutation in EGFR, which confers resistance to gefitinib and erlotini”
BackgroundAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 1×
“The best characterized BH3 mimetic is ABT-737, generated by Abbott Laboratories through a combination of NMR-based screening, parallel synthesis and structure-based desig”
BackgroundTargeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Cited by
Items 101–182 of 182
PI3K inhibition potentiates Bcl‐2‐dependent apoptosis in renal carcinoma cells
Zhu, S., Cohen, M. B., Bjorge, J. D., Mier, J. W., & Cho, D. C. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12019 · Cited by 20
Delbridge, A. R. D., Grabow, S., Bouillet, P., Adams, J. M., & Strasser, A. (2014) · Oncogene · doi:10.1038/onc.2014.132 · Cited by 23
Self-citationLi, X., Li, B., Ni, Z., Zhou, P., Wang, B., He, J., Xiong, H., Yang, F., Wu, Y., Lyu, X., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0763 · Cited by 24
“This combinatory strategy is in accord with the "synthetic lethal effect" that although oncogenic kinase inhibitors typically evoke cytostatic function, additional BCL-XL/BCL-2 inhibitors tip the balance to trigger prominent killing responses (30, 31).”
ResultStructure-Function Analysis of the Mcl-1 Protein Identifies a Novel Senescence-regulating Domain
Demelash, A., Pfannenstiel, L. W., Tannenbaum, C. S., Li, X., Kalady, M. F., DeVecchio, J., & Gastman, B. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.663898 · Cited by 27
“Encouraging results using small molecule inhibitors in both murine studies and human clinical trials have identified antiapoptotic Bcl-2 family members, especially Mcl-1, as attractive targets for cancer therapy (37).”
BackgroundThe apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells
Lee, H. Y., Kim, I. K., Lee, H. I., Mo, J. Y., Yeo, C. D., Kang, H. H., Moon, H. S., & Lee, S. H. (2016) · Experimental Lung Research · doi:10.3109/01902148.2015.1125970 · Cited by 24
“Bcl-2-like 11 (BIM) is a Bcl-2-homology domain 3only (BH3-only) protein and a key modulator of apoptosis, which upregulates mitochondrial apoptosis.[5, 6]”
BackgroundBroustas, C. G., Ross, J. S., Yang, Q., Sheehan, C. E., Riggins, R. B., Noone, A., Haddad, B. R., Seillier‐Moiseiwitsch, F., Kallakury, B., Haffty, B. G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2351 · Cited by 23
“The Bcl-2 family of proteins plays a pivotal role in the control of cell death and response of cancer cells to antineoplastic drugs and γ-radiation (1, 2).”
BackgroundNovel cancer therapies: treatments driven by tumour biology
Ramaswami, R., Harding, V., & Newsom-Davis, T. E. (2013) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-131533 · Cited by 25
Role for PKC in Fenretinide-Mediated Apoptosis in Lymphoid Leukemia Cells
Ruvolo, V. R., Karanjeet, K. B., Schuster, T. F., Brown, R. E., Deng, Y., Hinchcliffe, E. H., & Ruvolo, P. P. (2010) · Journal of Signal Transduction · doi:10.1155/2010/584657 · Cited by 21
“Fenretinide promoted reactive oxygen species (ROS) generation.”
Grabow, S., Waring, P., Happo, L., Cook, M., Mason, K. D., Kelly, P. N., & Strasser, A. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.133 · Cited by 20
Self-citationSakuma (2010) · Oncology Reports · doi:10.3892/or.2010.1123 · Cited by 18
The Discovery of Navitoclax, a Bcl-2 Family Inhibitor
Wendt, M. D. (2012) · Topics in medicinal chemistry · doi:10.1007/978-3-642-28965-1_7 · Cited by 18
ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line
Hwang, E., Hwang, S.-H., Kim, J.-J., Park, J. H., Oh, S., Kim, Y. A., & Hwang, K. (2018) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2018.95.5.240 · Cited by 19
“ABT-737, a small molecule that mimics the action of pro-apoptotic Bcl-2 homology domain 3-only proteins, has been shown to bind and neutralize pro-survival proteins Bcl-2, Bcl-xL, and Bcl-w, but not Mcl-1 or A1 [11].”
BackgroundRASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines
Levesley, J., Lusher, M. E., Lindsey, J. C., Clifford, S. C., Grundy, R. G., & Coyle, B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor129 · Cited by 23
“Evading apoptosis is a necessary prerequisite for malignant transformation, and restoration of apoptotic signaling could prove to be a major therapeutic strategy to reduce toxicity for patients and improve outcome.(31) Activation of BAX is inhibited by the anti-apoptotic BCL-2 family members.”
BackgroundShimada, K., Tomita, A., Minami, Y., Abe, A., Hind, C. K., Kiyoi, H., Cragg, M. S., & Naoe, T. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.05.007 · Cited by 17
“Although ABT-737 is not suitable for clinical practice due to poor physiochemical and pharmaceutical properties [38], the closely related Navitoclax (ABT-263), which is orally bioavailable, is in clinical development [37,39].”
BackgroundSelf-citationFine‐tuning the stimulation of MLL1 methyltransferase activity by a histone H3‐based peptide mimetic
Avdic, V., Zhang, P., Lanouette, S., Voronova, A., Skerjanc, I. S., & Couture, J.-F. (2010) · The FASEB Journal · doi:10.1096/fj.10-171959 · Cited by 16
Vera, M. B., Morris-Hanon, O., Nogueiras, G. I., Ripari, L. B., Esquivel, M. I., Perez-Castro, C., Romorini, L., Sevlever, G. E., Scassa, M. É., & Videla-Richardson, G. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-20910-4 · Cited by 16
Steen, T. V., Espinoza, I. C., Duran, C., Casadevall, G., Serrano‐Hervás, E., Cuyàs, E., Verdura, S., Kemble, G. W., Kaufmann, S. H., McWilliams, R. R., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101143 · Cited by 20
“…BCL-X L , MCL-1), thereby interfering with their functional ability to sequester the pro-apoptotic, BH3-only BCL-2 family members (e.g., BIM, BID, BAD, PUMA, and NOXA), which ultimately trigger the mitochondrial apoptotic pathway by inducing the homo-oligomerization of BAX/BAK effectors [22 – 27].”
Review on Radiation Therapy on Cancer
Dhakad, G. G., Patil, G. D., Nikum, A. C., & Shirsat, S. P. (2022) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2022.00002 · Cited by 14
A downside to apoptosis in cancer therapy?
Connell, P. P., & Weichselbaum, R. R. (2011) · Nature Medicine · doi:10.1038/nm0711-780 · Cited by 15
The prognostic importance of TGF-β, TGF-β receptor, and fascin in childhood solid tumors
Tanyıldız, H. G., Kaygusuz, G., Ünal, E., Taçyıldız, N., Dincaslan, H. U., & Yavuz, G. (2017) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2017.1363838 · Cited by 14
Finding and Drugging the Vulnerabilities of RAS-Dependent Cancers
Sawyers, C. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.011 · Cited by 14
“Indeed, much recent work has established that some cancer cells are poised to die but are rescued by hyperexpression of prosurvival proteins and that this vulnerability can be exploited clinically with Bcl-2 antagonists such as ABT-737 (Cragg et al., 2009; Letai, 2008).”
BackgroundEvaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis
Lawlor, K. E., Smith, S. D. G., van Nieuwenhuijze, A. E. M., Huang, D. C. S., & Wicks, I. P. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311174 · Cited by 13
“It is currently undergoing evaluation for the treatment of malignant conditions [32].”
BackgroundAnisuzzaman, A. S. M., Haque, A., Rahman, M. A., Wang, D., Fuchs, J. R., Hurwitz, S. J., Liu, Y., Sica, G., Khuri, F. R., Chen, Z., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0240 · Cited by 14
Co-targeting MCL-1 and ERK1/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells
Winkler, M., Friedrich, J., Boedicker, C., & Dolgikh, N. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101313 · Cited by 15
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58753-y · Cited by 11
“Inhibition of MEK/ERK signaling leads to BIM accumulation and increases apoptotic priming in oncogene-driven cancers treated with various targeted therapies, driving cells into an MCL-1 and/or BCL-XL dependent state 15,17 .”
Ezzoukhry, Z., Louandre, C., François, C., Saidak, Z., Godin, C., Mazière, J., & Galmiche, A. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.070565 · Cited by 15
“ABT-737 exerts modest cytotoxic effects when it is applied on cancer cells as a single agent (Oltersdorf et al., 2005), but a potent synergistic proapoptotic effect results from its coapplication with oncogenic kinase inhibitors (Cragg et al., 2008, 2009; Galmiche et al., 2010; Hikita et al., 2010).”
BackgroundCircSLC39A8 attenuates paclitaxel resistance in ovarian cancer by regulating the miR‑185‑5p/BMF axis
Liu, Y., Shen, Z., Wei, X., Gu, L., Zheng, M., Zhang, Y., Cheng, X., Fu, Y., & Lü, W. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101746 · Cited by 11
“BMF, is described as a BH3-only protein that belongs to the Bcl-2 protein family [39].”
BackgroundInhibitors Targeting the F-BOX Proteins
Naseem, Y., Zhang, C., Zhou, X., Dong, J., Xie, J., Zhang, H., Agboyibor, C., Bi, Y., & Liu, H. (2023) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-023-01160-1 · Cited by 16
“Suppose any genomic deletion and mutation has occurred that causes different types of human cancer [102, 103].”
BackgroundNew Frontiers in Cancer Chemotherapy — Targeting Cell Death Pathways
Xu, Y. Z., Kanagaratham, C., Youssef, M., & Radzioch, D. (2016) · InTech eBooks · doi:10.5772/61260 · Cited by 13
“Several preclinical studies have shown promising effects of combinatorial use of ATB263 with conventional cytotoxic agents or targeted therapy in both solid tumor and hematologic malignancy models [210, 213].”
BackgroundZhu, H., Liu, L., Fan, L., Zhang, L., Fang, C., Zou, Z., Li, J., & Xu, W. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.787613 · Cited by 11
Cell Death and Cancer, Novel Therapeutic Strategies
Grasso, S., Fernández-Pérez, M. P., Carrasco-Garca, E., Mayor-López, L., Tristante, E., Rocamora‐Reverte, L., Gmez-Martnez, N., García-Morales, P., Jos, A., Saceda, M., et al. (2012) · InTech eBooks · doi:10.5772/51285 · Cited by 12
“ABT-263 is currently in phase I and II clinical trails as a single agent [78,188].”
BackgroundMarca, J. E. L., Kelly, G. L., Strasser, A., & Diepstraten, S. T. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.06.018 · Cited by 11
Self-citationLi, Y., Zhou, G., La, L., Chi, X., Cao, Y., Liu, J., Zhang, Z., Chen, Y., & Wu, B. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.05.005 · Cited by 10
Emerging therapies for B-cell non-Hodgkin lymphoma
Briones, J. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.86 · Cited by 11
Happo, L., Strasser, A., & Scott, C. L. (2009) · Wiley eBooks · doi:10.1002/9780470015902.a0021569 · Cited by 9
Self-citationBuschner, G., Feuerecker, B., Spinner, S., Seidl, C., & Essler, M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1839648 · Cited by 8
Taking control of the female fertile lifespan: a key role for Bcl-2 family proteins
Liew, S. H., Vaithiyanathan, K., & Hutt, K. J. (2014) · Reproduction Fertility and Development · doi:10.1071/rd14326 · Cited by 7
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia
Ding, H., Vincelette, N. D., McGehee, C. D., Kohorst, M. A., Koh, B. D., Venkatachalam, A., Meng, X. W., Schneider, P. A., Flatten, K. S., Peterson, K. L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1504 · Cited by 7
“triggered bymany kinase inhibitors, BH3mimetics, and other targeted agents (18, 43).”
BackgroundA novel BIM deletion polymorphism: implications and lessons for cancer targeted therapies.
Soh, S. X., & Ong, S. T. (2013) · PubMed · Cited by 6
McNamara, M. C., Hosios, A. M., Torrence, M. E., Zhao, T., Fraser, C. S., Wilkinson, M. E., Kwiatkowski, D. J., Henske, E. P., Wu, C., Sarosiek, K. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105458 · Cited by 8
Function of myeloid cell leukaemia-1 and its regulative relations with hepatocellular carcinoma
Zhu, M., & Zhang, Y. (2017) · Hepatoma Research · doi:10.20517/2394-5079.2017.14 · Cited by 5
“Nevertheless, owing to low affinity with Mcl-1, ABT- Hepatoma Research ¦ Volume 3 ¦ July 06, 2017 737-mediated apoptosis signaling was inhibited in HCC cells due to the elevated expression of Mcl-1 which may contribute to HCC resistance to ABT737.”
BackgroundAn Update of Venetoclax and Obinutuzumab in Chronic Lymphocytic Leukemia
Salvaris, R., & Opat, S. (2020) · Future Oncology · doi:10.2217/fon-2020-0640 · Cited by 5
BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA -Mutant Colorectal Cancer
DeStefanis, R. A., Schmitz, A. E., Steimle, A. K., Payne, S. N., Sha, G. C., Olson, A. M., Cornelio, A. B., Lippert, A. E. L., Kraus, S. G., Johnson, K. A., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-1096 · Cited by 6
Cell‐based high‐throughput screen for small molecule inhibitors of Bax translocation
Hui, K. K., Soeandy, C. D., Chang, S. J., Vizeacoumar, F. S., Sun, T., Datti, A., & Henderson, J. T. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14076 · Cited by 5
“gested from several studies aimed at enhancing apoptotic response through the inhibition of anti‐apoptotic Bcl‐2 family members.(15) As a result, the small molecules ABT‐737 and derivative ABT‐263 were identified to inhibit the activity of Bcl‐2, Bcl‐xL and Bcl‐w interac-”
BackgroundRégulation de la survie cellulaire par les kinases de la famille RAF
Galmiche, A., & Ezzoukhry, Z. (2010) · médecine/sciences · doi:10.1051/medsci/2010268-9729 · Cited by 4
“Sur la base de ces nouvelles données, des travaux récents suggèrent l’efficacité d’un nouveau type d’association pharmacologique dans le traitement des cancers, avec d’une part des composés interférant avec les protéines BCL2, et d’autre part les thérapies ciblées antagonisant la voie RAF [35].”
BackgroundHuang, J.-L., & Yang, S.-X. (2009) · Saudi Medical Journal · doi:10.15537/1658-3175.4820 · Cited by 3
Histone modification as a drug resistance driver in brain tumors ⁎
Xi, G., Mania-Farnell, B. L., Lei, T., & Tomita, T. (2016) · Oncology and Translational Medicine · doi:10.1007/s10330-016-0165-5 · Cited by 3
Kameswaran, M., Sharma, R., Pandey, U., & Dash, A. K. (2020) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_20_19 · Cited by 3
Cell Proliferation, Survival, Necrosis and Apoptosis
Mierke, C. T. (2020) · Biological and medical physics, biomedical engineering · doi:10.1007/978-3-030-58532-7_16 · Cited by 5
Cell Biology of Prostate Cancer and Molecular Targets
Gleave, M. E., Cox, M., & Wang, Y. Z. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_1 · Cited by 4
“prosurvival molecules with Bax and/or Bak [110, 111].”
Adjuvant Approach to Mitigate the Adverse Effects of Cancer Treatments Using Homeopathic Medicines
Gupta, P. K., Kumar, A., Sharma, M., & Prajapati, S. (2022) · Current Cancer Therapy Reviews · doi:10.2174/1573394718666220512163517 · Cited by 3
Where now for anti-EGF receptor therapies in colorectal cancer?
Shaw, P. H., & Adams, R. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.143 · Cited by 3
Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs
Gangoda, L., Schenk, R. L., Tai, L., Szeto, P., Cheung, J. G., Strasser, A., Lessène, G., Shackleton, M. J., & Herold, M. J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04776-y · Cited by 3
Self-citationPickering, C. R., & Myers, J. N. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0019 · Cited by 2
Bozhdansky, V., Tayar, S., Kashkash, S., Bacharach, E., & Ehrlich, M. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02823-1 · Cited by 1
“Despite their ability to selectively activate apoptotic caspases in multiple cancer cell types and their successful use in treating blood cancers, BH3 mimetics are ineffective as monotherapy for most solid tumors [20].”
From molecules and cells to diseases: West meets East for medical research in Tianjin
Liu, J. (2009) · Cell Research · doi:10.1038/cr.2009.85 · Cited by 1
Targeting apoptosis is the major battle field for killing cancers
Liu, X. (2015) · World Journal of Translational Medicine · doi:10.5528/wjtm.v4.i3.69 · Cited by 1
Bio-mimetic strategies to re-activate apoptotic cell death for cancer treatments
Venerando, A., Lovison, D., & Marco, R. D. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00074 · Cited by 1
Targeting the Bcl-2 Family in B-Cell Chronic Lymphocytic Leukemia
Fais, F., Tenca, C., Ghiotto, F., & Bruno, S. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.43 · Cited by 1
Molekular zielgerichtete Krebstherapien bei Tumoren im Kindesalter
Fulda, S. (2011) · Der Onkologe · doi:10.1007/s00761-011-2152-3 · Cited by 1
BH3-Only Proteins in Cancer and Apoptosis
Ghiotto, F., Tenca, C., Fais, F., & Bruno, S. (2013) · Springer eBooks · doi:10.1007/978-94-007-6211-4_9
“2007), potentiates the activity of therapeutic agents (Kang et al. 2007; Cragg et al. 2009), and counteracts human tumor growth in mouse xenograft models (Konopleva et al.”
BackgroundRoles of protein kinase C in cell death and breast cancer
Cornmark, L. (2013) · Lund University Publications (Lund University)
Alewine, C. (2014) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_65-4
Variability and Dynamics of Apoptotic Events in Single Cells
Bhola, P. D. (2010) · Digital Commons - RU (Rockefeller University) · doi:10.48496/yj4x-j922
Control of Cell Survival and Apoptosis
Gray, D. H. D., & Strasser, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.11009-4
Self-citationCartlidge, R. C. (2015) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 1
Peckham-Cooper, A. (2017) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Targeting Cancer from a Structural Biology Perspective
Reid, D. F., & Mattos, C. (2019) · Springer eBooks · doi:10.1007/978-981-32-9816-3_12
A brief Overview of a Fatal Disease Namely Cancer
Maddheshiya, P. K., & Kumar, M. (2021) · Current Research in Pharmaceutical Sciences · doi:10.24092/crps.2021.110102
Hassane, D. C., & Guzmán, M. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_29
Campomanesia adamantium e Campomanesia guaviroba
Pascoal, A. C. R. F. (2015) · doi:10.47749/t/unicamp.2015.947928
Alewine, C. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_65
Lyberg, K., Nilsson, G. P., & Westerberg, C. M. (2015) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000153
“The small molecular inhibitor ABT-737, developed as a mimetic of the proapoptotic BH3-only protein Bad and known to induce apoptosis and have anti-tumour properties [14,21], has little effect as a single agent on a variety of human cancer cell lines, but acts synergistically with low doses of other chemotherapeutic ag…”
BackgroundInhibition of the TPL2-MKK1/2-ERK1/2 pathway has cytostatic effect on B-Cell LymphomaPreprint
Asslan, M., Martel, G., & Rousseau, S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.13.495940
“It had been postulated that oncogenic kinase inhibitors efficacy may be boosted by the presence of BCL-2 inhibitors (Cragg et al., 2009).”
BackgroundBim induction may be insufficient for driving Bax translocation to mitochondriaPreprint
Abrahams, L. (2022) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/5ya6q
Ding, H., Vincelette, N. D., McGehee, C. D., Kohorst, M. A., Koh, B. D., Venkatachalam, A., Meng, X. W., Schneider, P. A., Flatten, K. S., Peterson, K. L., et al. (2023) · doi:10.1158/0008-5472.c.6512716.v1
Vogler, M., Furdas, S. D., Jung, M., Kuwana, T., Dyer, M. J. S., & Cohen, G. M. (2023) · doi:10.1158/1078-0432.c.6518951.v1
Radiotherapy and targeted therapy – a review of the literature
Kruczała, M., & Sas-Korczyńska, B. (2023) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2023.0013
Control of Cell Survival and Apoptosis
Gray, D. H. D., & Strasser, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00506-8
Self-citationRégulation du développement et de la fonction des cellules innées lymphoïdes NKp46+
Viant, C. (2016) · theses.fr (ABES) · doi:10.70675/3d6d7190z9e08z426fz9dfaz0bb48d4f7808
Etude in vivo de la chimiorésistance dans les leucémies aigues myéloïdes humaines
Aroua, N. (2018) · theses.fr (ABES) · doi:10.70675/87716ea3z1f4dz4a62zb041z59f2afc4c3e9
Metadata
- Authors
- Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L.
- Affiliations
- Walter and Eliza Hall Institute of Medical Research (AU)
- The Royal Melbourne Hospital (AU)
- Corresponding author
- Cragg, Mark S.
- Scott, Clare L.
- Venue
- Nature Reviews Cancer
- Published
- 2009-04-03
- Volume
- 9
- Issue
- 5
- Pages
- 321-326
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2065336454
- Cited by
- 185
- References
- 58
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 12 · 2021: 8 · 2020: 6 · 2019: 4 · 2018: 8 · 2017: 8 · 2016: 16 · 2015: 17 · 2014: 16 · 2013: 16 · 2012: 15
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- BH3 mimetics, ABT-737, apoptosis, targeted cancer therapy, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biphenyl Compounds, Humans, Nitrophenols, Piperazines, Sulfonamides, Fusion Proteins, bcr-abl, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.